Page 24 - Longeveron Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Longeveron Files Registration Statement for Rights Offering

Longeveron Files Registration Statement for Rights Offering
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

United statesExchange commissionLongeveron incLongeveron or companyAging frailtyOkapi partnersSecurities act

Longeveron Inc (NASDAQ:LGVN) Sees Significant Drop in Short Interest

Longeveron Inc. (NASDAQ:LGVN – Get Rating) saw a large drop in short interest during the month of May. As of May 31st, there was short interest totalling 269,300 shares, a drop of 33.3% from the May 15th total of 403,500 shares. Approximately 5.3% of the shares of the company are sold short. Based on an […]

Gamco investorsEf hutton acquisition coNorthern trust corpCitigroup incVanguard group incLongeveron company profileLongeveron incGet ratingTrust corpState street corpLongeveron dailyNasdaq lgvn

Longeveron Inc (NASDAQ:LGVN) Sees Large Decrease in Short Interest

Longeveron Inc. (NASDAQ:LGVN – Get Rating) was the target of a significant drop in short interest during the month of April. As of April 30th, there was short interest totalling 155,200 shares, a drop of 6.4% from the April 15th total of 165,800 shares. Approximately 3.4% of the shares of the company are short sold. […]

Gamco investorsNorthern trust corpVanguard group incEf hutton acquisition coLongeveron incCitigroup incGet ratingStreet corpLongeveron dailyNasdaq lgvn

Longeveron Inc (NASDAQ:LGVN) Q1 2023 Earnings Call Transcript

Operator: Good morning, and welcome to Longeveron s call today to discuss the company s 2023 First Quarter and Financial Results. All participants are currently in listen-only mode.

United statesJames clavijoMichael okunewitchMaxim groupNational heartLogicvision incLongeveron incBlood instituteCall transcript mayChief financial officerWa el hashadChief executive officerJoshua hareChief scientific officerChris minActing chief medical officer

Longeveron Inc Provides Corporate Update and Reports First Quarter 2023 Financial Results

12.05.2023 - - New long-term survival data disclosed from ELPIS I trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome; Data reinforce potential mortality benefit - - First patient dosed in Phase 2 clinical trial of Lomecel-BTM for Aging-Related Frailty .

United statesJames clavijoLongeveron incDrug administrationExchange commissionNational centerJuntendo university hospital tokyoStern ir incWa el hashadChief executiveAging related frailtyQuarter business updatesHypoplastic left heart syndromeFast trackRare pediatric diseaseOrphan drug designations